Oncogenex Pharmaceuticals Inc (NASDAQ:OGXI) Participates In The Push For Development Of Cystisine For Smoking Cessation

Biotech Stock News

OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), and Achieve Life Science, Inc. have today unveiled a strategic agreement with National Center for Complementary and Integrative Health (NCCIH) in what is said to be a new dawn that will oversee the establishment of non-clinical studies. The study is expected to help come up with a clinical development plan that will help assist those persons addicted to smoking and have had severe complications.

Smoking feels good for those smoking. However, it gets tricky when it comes to that point when complications start showing up. They affect the body function systems since smoking affects even the delicate organs such as the liver. It can get a lot much worse when the affected person move out there to go seek for treatment. The treatment is expensive and at times it is difficult to find someone well qualified to handle the complications. This as a result culminates into the loss of many lives.

Cytisine happens to be a drug that comes to the rescue of the affected persons. David Shurtleff, who is the Deputy Director, has indicated great optimism by saying that the research collaborations would go a long way towards helping in the development of more smoking cessation aids. As a result, it will be easy to help face out the many death cases that usually occur due to prolonged smoking.

The U.S. Surgeon General’s 2014 report has highlighted the various dangers that are associated with smoking. It goes ahead to reveal that over 16 million Americans struggle with complications emanating from smoking. 480,000 deaths occur due to the prolonged smoking habits. OncoGenex Pharmaceuticals, which is one of the Top Biotech Stocks, has a long way to go both in research and drug development.

The government has over time spearhead and sponsored campaigns to assist fight off the smoking habit. In those campaigns, people have been taught on the dangers of smoking, but is absurd that the habit goes on and on making the nation loose in terms early deaths .

Two studies have been carried out over time and the good news is that they produced favorable results. This should be good news for the government and for the addicts as well! In January 2017, achieve agreed to form a merger with OncoGenex Pharmaceuticals, a move that is hopefully going to help manufacture effective drugs to cure smoking related complications. If all goes well, new developments will be availed to the genera public in the Biotech Stock News.


Please enter your comment!
Please enter your name here